$ATAI

Biotech and healthcare stocks hit 52-week highs on Aug. 14, 2026 after quarterly results or acquisition news. Eton Pharmaceuticals (ETON) rose over 44% to $59.79; Q2 net product sales grew 99% YoY and profit was $11.6M. DexCom (DXCM) reached $91.96; Q2 revenue $1.31B (+13%) and 2026 revenue guidance $5.18B-$5.25B. Oruka (ORKA) touched $111.37; AtaiBeckley (ATAI) $7.28 after an Eli Lilly (LLY) deal potentially worth $3.8B. Concentra (CON) hit $35.52; Q2 revenue $606M (+10%) and profit $67M.

AtaiBeckley Inc. (ATAI) shares hit a 52-week high of $7.26, up 86.98% over one year and 77% year-to-date, according to Investing.com. The stock also moved after Eli Lilly agreed to acquire AtaiBeckley for $6.75 per share upfront, valuing it about $2.8B plus a contingent value right up to $2.50. Analysts issued mixed rating and price-target changes.

The article discusses how legalization of psychedelic medicine is increasing commercialization and regulatory costs for Schedule I research. It cites Eli Lilly’s $2.8 billion acquisition of Atai Life Sciences/AtaiBeckley and describes Oregon’s Measure 109, where psilocybin sessions cost $850 to $3,000 and OHA proposed higher fees. It also notes New Jersey’s pilot favoring synthetic psilocybin.

Eli Lilly agreed to acquire AtaiBeckley for $2.8 billion upfront, with up to $1 billion in milestone payments, according to the companies. Ark Genomic Revolution ETF sold Atai shares and bought Compass Pathways shares. The article cites Jefferies estimates of $1-2 billion peak sales for Atai’s BPL-003 and notes Compass’s COMP360 phase 3 results and potential 2026 NDA timing.

Eli Lilly agreed to acquire AtaiBeckley for $2.8 billion upfront, with up to $1 billion in milestone payments, according to the companies. Atai’s lead drug BPL-003 is in phase 3 for treatment-resistant depression, with Jefferies estimating peak sales of $1 billion to $2 billion. The article also notes Ark Genomic Revolution ETF trading in Atai and Compass, and highlights regulatory changes affecting psychedelic reviews.

The Wall Street Journal reports major drugmakers are funding synthetic 5-MeO-DMT, derived from Colorado River toad venom, seeking FDA approval for depression or other mental health uses. The compound is illegal in the US and can cause intense adverse experiences. Eli Lilly expanded into psychedelics by acquiring AtaiBeckley for $2.8 billion, gaining a breakthrough-designated analog. AtaiBeckley shares rose 253% since Jan 2025.

According to ARK’s published trades for July 24, 2026, ARK sold 718,303 shares of Figma Inc (FIG) for about $14.37M across ARKK and ARKW. It bought 361,253 shares of Scribe Therapeutics (SCTX) for about $5.42M and added to Compass Pathways (CMPS) for about $1.25M. It also sold ATAI Beckley (ATAI) and bought Kodiak AI (KDK), Pony AI (PONY), X-Energy (XE), and others.

Eli Lilly agreed to acquire AtaiBeckley for $2.8 billion, with up to $1 billion in milestone payments, to gain BPL-003, a Phase III fast-acting nasal spray for treatment-resistant depression. AtaiBeckley’s 15% stake gives founder Christian Angermayer about $360 million pre-tax. Phase III trials are expected to start in 2029.

Eli Lilly said it will acquire clinical-stage biotech AtaiBeckley for nearly $2.8B, with up to $1B in milestones, expected to close in September. The deal adds Atai’s BPL-003 (mebufotenin) in Phase 3 for treatment-resistant depression, plus Phase 2 programs VLS-01 and EMP-01. Lilly targets 2026 revenue of $82B to $85B.

Eli Lilly plans to acquire AtaiBeckley to expand its neuroscience pipeline, including rapid-acting neuroplastogens for treatment-resistant depression. The deal could be worth up to $3.8bn. AtaiBeckley’s lead candidate BPL-003 (mebufotenin benzoate) is in Phase 3 and has FDA Breakthrough Therapy Designation. Lilly also agreed deals for Centessa ($7.8bn) and Kelonia Therapeutics ($7bn).